GlassScriptPhysician profile
Deep Shikha
NPI 1356634265
$792.66
in general payments reported to CMS, 2019-2025
15 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.58 · 2020: $133 · 2021: $35.21 · 2022: $107 · 2023: $149 · 2024: $114 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.89 | 2021-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $106.58 | 2022-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $101.21 | 2020 | |
| Lilly USA, LLC | $74.48 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $70.53 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $39.31 | 2019-2020 | |
| Ucb, INC. | $37.08 | 2021-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.12 | 2019-2025 | Jardiance |
| Mannkind Corporation | $22.60 | 2019 | |
| Amgen INC. | $21.58 | 2025 | Tepezza |
| Ibsa Pharma INC. | $19.44 | 2022 | |
| Medtronic, INC. | $17.85 | 2024 | Minimed 780g |
| Embecta Corp. | $17.53 | 2024 | |
| Dexcom, INC. | $17.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Shikha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.